Can fezolinetant help treat depression?
Fezolinetant is a new type of neurokinin 3 receptor (NK3R) antagonist. Its main mechanism of action is to relieve common vasomotor symptoms such as hot flashes and night sweats in menopausal women by regulating the temperature regulation center of the hypothalamus. Although it acts on the central nervous system, there is currently no evidence that fezonatant has direct antidepressant effects. Its core target is the neurokininB pathway, rather than the traditional serotonin, dopamine or norepinephrine neural pathways, which means that its main pharmacological effects focus on body temperature regulation and nerve signal balance, rather than emotional regulation.

However, from an indirect perspective, fezonatant may indeed have a positive impact on improving depressive mood. As estrogen levels drop in menopausal women, they are often accompanied by hot flashes, insomnia, anxiety and mood swings, and these physical discomforts can further aggravate the psychological burden. Fezonetant helps patients restore a stable circadian rhythm by improving sleep quality, reducing night sweats and restlessness. This indirect improvement is often felt by some patients as "mood improvement." It's not that the drug itself has an antidepressant effect, but rather that the emotional state improves as physical symptoms are relieved.
In real-world data, some studies have pointed out that some patients reported "overall quality of life improvement" after using fezonatant, including improved sleep, recovery of daytime attention, etc., but these changes are mostly attributed to secondary psychological improvements brought about by symptom relief. Clinicians generally do not use filazonatant as a treatment for depression and do not recommend it interchangeably with antidepressants. If patients experience significant symptoms of depression or anxiety during menopause, they should receive psychological intervention or use proven antidepressant treatment under the guidance of a doctor.
Reference materials:https://www.veozah.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)